Free Trial

Y-mAbs Therapeutics (YMAB) News Today

Y-mAbs Therapeutics logo
$4.32 +0.19 (+4.60%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$4.32 0.00 (0.00%)
As of 05/23/2025 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

YMAB Latest News

Y-mAbs Therapeutics, Inc. stock logo
HC Wainwright Brokers Decrease Earnings Estimates for YMAB
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Investment analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for shares of Y-mAbs Therapeutics in a report issued on Monday, May 19th. HC Wainwright analyst R. Burns now expects that the company will post ear
HC Wainwright Brokers Reduce Earnings Estimates for YMAB
Y-mAbs Therapeutics, Inc. stock logo
FY2026 Earnings Forecast for YMAB Issued By HC Wainwright
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Stock analysts at HC Wainwright issued their FY2026 EPS estimates for shares of Y-mAbs Therapeutics in a report issued on Monday, May 19th. HC Wainwright analyst R. Burns forecasts that the company will earn ($0.92) per share for the year. H
Y-mAbs Therapeutics, Inc. stock logo
Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC Wainwright
HC Wainwright lowered their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a research note on Monday.
Y-mAbs Therapeutics, Inc. stock logo
D. E. Shaw & Co. Inc. Has $4.82 Million Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
D. E. Shaw & Co. Inc. reduced its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 21.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 615,131 shares of the company's stock after s
YMAB FY2025 EPS Forecast Raised by Cantor Fitzgerald
Y-mAbs Therapeutics, Inc. stock logo
Wedbush Cuts Earnings Estimates for Y-mAbs Therapeutics
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Research analysts at Wedbush decreased their Q2 2025 earnings per share estimates for Y-mAbs Therapeutics in a research report issued on Tuesday, May 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($
Wedbush Forecasts Reduced Earnings for Y-mAbs Therapeutics
Y-mAbs Therapeutics, Inc. stock logo
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eleven ratings firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, seven have given a buy recommend
Y-mAbs Therapeutics, Inc. stock logo
Paradigm Biocapital Advisors LP Grows Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
Paradigm Biocapital Advisors LP raised its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 3.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 4,236,346 shares of the company's stock after purchasing an additional 150,000 s
Y-mAbs Therapeutics, Inc. stock logo
Short Interest in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Drops By 16.1%
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 3,070,000 shares, a drop of 16.1% from the March 31st total of 3,660,000 shares. Based on an average daily volume of 400,200 shares, the days-to-cover ratio is presently 7.7 days. Currently, 8.9% of the company's stock are short sold.
Y-mAbs Therapeutics, Inc. stock logo
2,861,825 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Acquired by Acorn Capital Advisors LLC
Acorn Capital Advisors LLC acquired a new stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 2,861,825 shares of the company's stock, valued at approximately $22
Y-mAbs Therapeutics, Inc. stock logo
Caligan Partners LP Has $13.84 Million Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
Caligan Partners LP grew its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 47.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,767,982 shares of the company's stoc
Y-mAbs Therapeutics, Inc. stock logo
Renaissance Technologies LLC Raises Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
Renaissance Technologies LLC grew its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 371.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 131,600 shares of the company's stock after purchasing an addition
Y-mAbs Therapeutics, Inc. stock logo
Y-mAbs Therapeutics (YMAB) Projected to Post Earnings on Tuesday
Y-mAbs Therapeutics (NASDAQ:YMAB) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-y-mabs-therapeutics-inc-stock/)
Y-mAbs Therapeutics, Inc. stock logo
JPMorgan Chase & Co. Raises Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
JPMorgan Chase & Co. boosted its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 221.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 97,660 shares of the company's sto
Y-mAbs Therapeutics, Inc. stock logo
Boothbay Fund Management LLC Buys 136,264 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
Boothbay Fund Management LLC grew its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 24.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 693,693 shares of the company's stock after purchasing an additiona
Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA
Y-mAbs Therapeutics, Inc. stock logo
Brookline Capital Management Weighs in on YMAB Q1 Earnings
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Equities research analysts at Brookline Capital Management lowered their Q1 2025 earnings per share estimates for Y-mAbs Therapeutics in a research note issued to investors on Tuesday, April 22nd. Brookline Capital Management analyst K. Doll
Y-mAbs Therapeutics, Inc. stock logo
Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded to "Underperform" Rating by Bank of America
Bank of America cut shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective for the company. in a research report on Tuesday.
Y-mAbs Therapeutics downgraded to Underperform from Neutral at BofA
Y-mAbs downgraded to Underperform at BofA on tough near-term setup
Y-mAbs Therapeutics, Inc. stock logo
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eleven analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has
Y-mAbs Therapeutics, Inc. stock logo
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Update
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) was the target of a large decline in short interest during the month of March. As of March 31st, there was short interest totalling 3,660,000 shares, a decline of 17.6% from the March 15th total of 4,440,000 shares. Approximately 10.6% of the shares of the company are short sold. Based on an average trading volume of 426,500 shares, the days-to-cover ratio is presently 8.6 days.
Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc. stock logo
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Bought by Pictet Asset Management Holding SA
Pictet Asset Management Holding SA grew its position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 9.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 756,297 shares of the company's stock a
Y-mAbs Therapeutics, Inc. stock logo
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have received an average rating of "Moderate Buy" from the eleven research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating, seven hav
Y-mAbs Therapeutics, Inc. stock logo
HC Wainwright Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $12.00
HC Wainwright decreased their price objective on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating for the company in a report on Friday.
Get Y-mAbs Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.

YMAB Media Mentions By Week

YMAB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

YMAB
News Sentiment

0.33

0.75

Average
Medical
News Sentiment

YMAB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

YMAB Articles
This Week

14

4

YMAB Articles
Average Week

Get Y-mAbs Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:YMAB) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners